GleamWall
中文EN

AMPH Amphastar Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1297184 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.1%
TTM net income YoY-11.3%
TTM EPS YoY-3.5%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR-9.9%

Margins

Gross margin46.8%
Operating margin18.7%
Net margin13.3%
FCF margin18.6%
EBITDA margin22.4%

Returns

ROE12.4%
ROA5.9%
ROIC (approx.)8.9%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets52.4%
Debt / equity0.75x
Current ratio3.32x
Interest coverage5.25x

Cash quality & payout

Operating cash flow / net income1.77x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue4.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$719.89M$731.97M
Cost of revenue$363.83M$358.11M
Gross profit$356.06M$373.86M
R&D expense$85.84M$73.91M
SG&A expense$85.92M$56.72M
Operating income$140.40M$205.42M
Interest expense$25.48M$30.34M
Pretax income$123.62M$189.76M
Income tax$25.53M$29.67M
Net income$98.09M$159.52M
EBITDA$172.05M$233.67M
EPS (basic)2.103.29
EPS (diluted)2.033.06
Weighted avg. shares (diluted)48.22M52.06M
Balance sheet
Cash & equivalents$170.18M$151.84M
Short-term investments$112.64M$70.04M
Receivables$143.56M$136.29M
Inventory$176.89M$153.74M
Current assets$636.02M$534.07M
PP&E, net$310.57M$297.35M
Goodwill$3.40M$3.05M
Intangibles$533.34M$558.39M
Total assets$1.63B$1.58B
Current liabilities$158.16M$173.76M
Short-term debt$1.64M$234,000
Long-term debt$608.75M$601.63M
Total debt$610.39M$601.86M
Total liabilities$840.49M$845.17M
Shareholders' equity$788.80M$732.30M
Net debt$440.21M$450.02M
Shares outstanding45.65M47.62M
Cash flow statement
Operating cash flow$156.12M$213.39M
Capital expenditure$34.88M$41.04M
Free cash flow$121.23M$172.34M
Investing cash flow-$70.33M-$124.93M
Financing cash flow-$67.42M-$80.95M
Depreciation & amortization$31.65M$28.25M
Stock-based compensation$27.28M$24.37M
Share buybacks$75.59M$85.46M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.